ACR Convergence 2020 highlights

“The Great Debate” of the ACR Convergence 2020 virtual meeting addressed the question of whether JAK inhibitors should be given before biologics following an inadequate response to methotrexate in patients with rheumatoid arthritis.

Secukinumab significantly reduces spinal pain in patients with axial spondyloarthritis, with benefits seen after just 8 weeks, findings from the SKIPPAIN trial show.

BIIB059, a monoclonal antibody that binds blood dendritic cell antigen 2 and inhibits interferon 1, improves total active joint count at 24 weeks in patients with systemic lupus erythematosus, findings from the LILAC trial show.

Phase 3 trial results suggest that secukinumab treatment reduces synovitis among biologic-naïve patients with psoriatic arthritis and an inadequate response to conventional DMARDs.

Among rheumatoid arthritis patients in sustained remission on combination therapy, withdrawal of methotrexate is associated with better outcomes than withdrawal of etanercept, indicate findings from the SEAM-RA trial.

The IL-17A inhibitor secukinumab may improve pain and disease activity among patients with psoriatic arthritis or axial spondyloarthritis and imaging-confirmed enthesitis at the Achilles tendon, suggest findings from the ACHILLES trial.